Quoin Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -6.71, missing the estimate of USD -6.36.

EBIT: As of FY2025 Q3, the actual value is USD -4.082 M.

Segment Revenue

• Quoin Pharmaceuticals, Ltd. has not generated any revenue as of September 30, 2025, since the company has not yet commercialized any products.

Operational Metrics

• Net Loss: The company reported a net loss of $3,948,165 for the three months ended September 30, 2025, compared to a net loss of $2,349,885 for the same period in 2024, marking an increase of $1,598,280.
• Total Operating Expenses: Total operating expenses were $4,019,925 for the three months ended September 30, 2025, up from $2,528,002 in the same period in 2024.
• General and Administrative Expenses: These expenses increased by $290,369, or approximately 20%, to $1,738,751 for the three months ended September 30, 2025, compared to $1,448,382 for the same period in 2024.
• Research and Development Expenses: These expenses rose by $1,201,554, or approximately 111%, to $2,281,174 for the three months ended September 30, 2025, compared to $1,079,620 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $8,505,969, compared to $5,620,790 for the same period in 2024.
• Net Cash Provided by Investing Activities: The company reported net cash provided by investing activities of $6,990,574 for the nine months ended September 30, 2025, compared to $1,290,037 for the same period in 2024.
• Net Cash Used in Financing Activities: For the nine months ended September 30, 2025, net cash used in financing activities was $277,042, compared to net cash provided by financing activities of $5,046,305 for the same period in 2024.

Unique Metrics

• Stock-Based Compensation: The company recorded stock-based compensation expenses of approximately $182,000 for the three months ended September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: Quoin Pharmaceuticals, Ltd. plans to complete the late-stage clinical testing of QRX003 for Netherton Syndrome and, if successful, file for marketing approval in the United States, Europe, Japan, and other territories. The company also aims to prepare for commercialization by establishing its own sales infrastructure in key markets and entering into distribution partnerships in other regions.
• Non-Core Business: The company has entered into nine commercial partnerships for QRX003 spanning 61 countries outside of its core commercial territories, including Canada, Australia/New Zealand, the Middle East, China, and several countries in Latin America.